- Mersana Therapeutics press release (NASDAQ:MRSN): Q3 GAAP EPS of -$0.61 misses by $0.60.
- Revenue of $5.57M (vs. $0.01M) misses by $51.21M.
- Cash, cash equivalents and marketable securities as of September 30, 2022, were $290.1M, compared to cash and cash equivalents of $177.9M as of December 31, 2021. Mersana expects that its available funds will be sufficient to support its operating plan commitments into the first half of 2024.
Mersana Therapeutics GAAP EPS of -$0.61 misses by $0.60, revenue of $5.57M misses by $51.21M
Recommended For You
More Trending News
About MRSN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MRSN | - | - |
Mersana Therapeutics, Inc. |